Garde Capital’s BioNTech BNTX Stock Holding History

Garde Capital’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-50	Closed	-$5.32K	–	326
2025 Q2	$5.32K	Buy	+50	New	+$5.05K	﹤0.01%	558

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Garde Capital's BNTX Position: Q3 2025 in Review

Garde Capital sold out of BioNTech (BNTX) in Q3 2025, closing a stake of 50 shares — an estimated $5.32K sold.

Garde Capital first reported a position in BNTX in Q2 2025 and held it in 1 quarter. The position peaked at $5.32K in Q2 2025. 254 funds tracked by Wall St. Rank hold BNTX as of Q3 2025.

Garde Capital reported no remaining BioNTech position as of Q3 2025 after selling out during the quarter.
Garde Capital sold 50 BioNTech shares in Q3 2025, an estimated $5.32K.
Garde Capital first reported a position in BioNTech in Q2 2025 and held it in 1 quarter.
Garde Capital's BioNTech position peaked at $5.32K in Q2 2025.
254 funds tracked by Wall St. Rank held BioNTech as of Q3 2025.

Based on Garde Capital's 13F filing for Q3 2025, filed 16 Dec 2025.